Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Key Points

• Kras g12c and egfr inhibitors face resistance challenges in colorectal cancer treatment.
• Baseline alterations were identified in colorectal cancer patients who developed resistance to inhibitors.
• An oncoprint visualization effectively displays genetic changes associated with resistance mechanisms.
• Understanding resistance patterns can inform better therapeutic approaches for colorectal cancer patients.